The regents of the university of california (20240294657). INHIBITING ANTI-ENPP1 ANTIBODIES simplified abstract
INHIBITING ANTI-ENPP1 ANTIBODIES
Organization Name
the regents of the university of california
Inventor(s)
Arjun Deb of Los Angeles CA (US)
INHIBITING ANTI-ENPP1 ANTIBODIES - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240294657 titled 'INHIBITING ANTI-ENPP1 ANTIBODIES
- Simplified Explanation:**
This patent application discusses inhibitory anti-ENPP1 antibodies and their fragments for treating myocardial infarction. It also covers nucleic acid molecules encoding these antibodies, methods of production, and pharmaceutical compositions containing them.
- Key Features and Innovation:**
- Inhibitory anti-ENPP1 antibodies for treating myocardial infarction - Nucleic acid molecules encoding these antibodies - Methods of producing the antibodies using host cells - Pharmaceutical compositions containing the antibodies
- Potential Applications:**
- Treatment of myocardial infarction - Development of new therapies for cardiovascular diseases - Research in the field of antibody-based treatments
- Problems Solved:**
- Lack of effective treatments for myocardial infarction - Need for targeted therapies for cardiovascular diseases - Challenges in antibody production and formulation
- Benefits:**
- Improved treatment options for myocardial infarction - Potential for personalized medicine approaches - Enhanced understanding of ENPP1 biology and its role in cardiovascular health
- Commercial Applications:**
Title: "Inhibitory Anti-ENPP1 Antibodies for Cardiovascular Therapy" This technology could be used in pharmaceutical companies to develop novel treatments for myocardial infarction and other cardiovascular conditions. It may have significant market implications in the field of cardiology and personalized medicine.
- Questions about Inhibitory Anti-ENPP1 Antibodies:**
1. How do inhibitory anti-ENPP1 antibodies differ from traditional treatments for myocardial infarction?
- Inhibitory anti-ENPP1 antibodies target a specific enzyme involved in cardiovascular health, offering a more targeted approach compared to conventional therapies.
2. What potential challenges could arise in the production and clinical use of these antibodies?
- Possible challenges may include scalability of production, regulatory approval processes, and patient-specific responses to the treatment.
Original Abstract Submitted
in certain aspects, provided herein are inhibitory anti-enpp1 antibodies and antigen binding fragments thereof. in some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. in certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. in some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.